Related Experiment Video
Updated: Jul 11, 2025
10:34
A High-content Assay for Monitoring AMPA Receptor Trafficking
Published on: January 28, 2019
7.7K
P2X7 Receptor: an Emerging Target in Alzheimer's Disease
Qiang Huang1,2, Jun Ying1,2, Wen Yu1,2
1Department of Anesthesiology, the Second Affiliated Hospital of Nanchang University, 1# Minde Road, Nanchang, 330006, Jiangxi, China.
Molecular Neurobiology
|November 8, 2023
Summary
The P2X7 receptor (P2X7R) is upregulated in Alzheimer's disease (AD), contributing to key pathological processes. Targeting P2X7R offers a potential strategy to slow AD progression.
Area of Science:
- Neuroscience
- Pathology
- Pharmacology
Background:
- Alzheimer's disease (AD) is a leading cause of dementia with complex, not fully understood, pathogenesis.
- Current treatments and diagnostic tools for AD are limited, highlighting the need for novel therapeutic targets.
- Increasing evidence links P2X7 receptor (P2X7R) upregulation to AD pathology, including amyloid plaques and neuroinflammation.
Purpose of the Study:
- To review the current understanding of P2X7R's role in Alzheimer's disease.
- To explore P2X7R's involvement in AD-related pathological mechanisms.
- To suggest P2X7R-targeted pharmacological interventions for AD.
Main Methods:
- Literature review of studies investigating P2X7R in Alzheimer's disease.
- Analysis of P2X7R's involvement in key AD pathological hallmarks.
- Synthesis of information on P2X7R's function in neuroinflammation and oxidative stress.
Main Results:
- P2X7R expression is elevated in Alzheimer's disease.
- P2X7R is implicated in the development of amyloid plaques and neurofibrillary tangles.
- P2X7R activation contributes to oxidative stress and chronic neuroinflammation in AD.
Conclusions:
- P2X7 receptor is a significant factor in Alzheimer's disease development.
- P2X7R represents a promising therapeutic target for mitigating AD progression.
- Pharmacological modulation of P2X7R may offer new avenues for AD treatment.
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197
01:26Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.3K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.3K